<unk>  is indicated for the following: * To lower the risk of stroke and embolism in people with nonvalvular atrial fibrillation. * Deep vein thrombosis (DVT) prevention. DVTs may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. * Treatment of both DVT and PE. * To reduce the risk of recurring DVT and PE after initial therapy. In the EU,<unk>  is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and for the prevention of recurrent DVT and PE in adults. Atrial fibrillation<unk>  is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes mellitus, or symptomatic heart failure.<unk>  and other anticoagulants (dabigatran, edoxaban and rivaroxaban) appear equally effective as warfarin in preventing non-hemorrhagic stroke in people with atrial fibrillation and are associated with lower risk of intracranial bleeding. While<unk>  may be used in people with severely decreased kidney function and those on hemodialysis it has not been studied in these groups. Full dose<unk>  (5 mg bid) can be used, unless at least two of the following characteristics apply: patient age is 80 years or older, body weight is 60 kg or less, and serum creatinine is 1.5 mg/dL or higher, in which case dose reduction to 2.5 mg bid is indicated.
Apixaban
Enoxaparin sodium
Dabigatran
Rivaroxaban
Palladin
Ticlopidine
Eptifibatide
Ticagrelor